Format

Send to

Choose Destination
Head Neck. 2002 Aug;24(8):792-9.

Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.

Author information

1
Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.

Abstract

Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is overexpressed in a variety of premalignant and malignant conditions, including oral leukoplakia and squamous cell carcinoma of the head and neck. Increased levels of COX-2 may contribute to carcinogenesis by modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. In experimental models, newly developed selective COX-2 inhibitors suppress the formation of tumors, including tongue cancer. These findings provided a rationale for a number of chemoprevention trials that are underway. Selective COX-2 inhibitors also suppress the growth and metastases of established tumors and enhance the anticancer activity of both radiotherapy and chemotherapy in experimental animals. In this review, evidence is presented that inhibition of COX-2 represents a promising strategy to prevent or possibly treat human head and neck cancers.

PMID:
12203806
DOI:
10.1002/hed.10108
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center